Abstract: Disclosed herein are substituted piperazine late Na+ channel modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Methods for preparing improved Panax Notoginseng saponin fraction from a Sanchi extract and its use in pharmaceutical compositions for treating or preventing a blood circulation disorder.

Abstract: The invention discloses an ethyl acetate layer of methanol extract of Aquilaria hulls for killing cancer cells and treating/preventing cancers and its uses. The extracts of Aquilaria hulls has an significant amount of cucurbitacins and these cucurbitacins are effective in killing cancer cells and treating/preventing cancers.

Abstract: A sugar-cholestanol compound which can be readily synthesized and which exhibits a satisfactory antitumor activity. An anticancer agent containing, as an active ingredient, a cholestanol compound represented by the following formula (1): or a cyclodextrin inclusion complexation containing the compound. A method for treating cancer using this compound.

Abstract: The present invention relates to the use of known and novel compounds as inhibitors of UDP-GlcNAc:Gal?1,3GalNAc-R (GlcNAc to GalNAc) ?1,6-N-acetylglucosaminyl transferase (core 2 ?1,6 N-acetylaminotransferase, core 2 GlcNAc-T-EC 2.4.1.102). Such inhibitors have applications in therapy for diseases associated with raised activity of core 2 GlcNAc-T, in particular inflammatory diseases, atherosclerosis, diabetic cardiomyopathy, cancers—including treatment or prevention of metastasis—or diabetic retinopathy.

Abstract: The present invention disclosed a medical use of cucurbitane triterpenoids represented by the following formula and isolated from Momordica charantia L. of Cucurbitaceae family in the preparation of medications for prevention and treatment of diabetes and obesity. The above cucurbitane triterpenoids may be acted as a glucose uptake stimulator, an agonist for the translocation of glucose transporter 4(GLUT4) to the cell membrane, and an activator of adenosine monophosphate-activated protein kinase (AMPK). They may have potential for the prevention and treatment of diabetes and obesity.

Abstract: The invention provides a method for determining if a subject has atherosclerosis, including: determining an endogenous microRNA-195 expression level of a subject suspected of having atherosclerosis; and comparing the endogenous microRNA-195 expression level of the subject with an endogenous microRNA-195 expression level of a normal group, wherein an increase in the endogenous microRNA-195 expression level of the subject as compared to the endogenous microRNA-195 expression level of the normal group indicates that the subject has atherosclerosis.

Abstract: The composition of a dietary supplement is provided for increasing post workout recovery, increasing replenishment and regaining energy following exercise. A method for achieving the same is also provided. The present composition comprises branched chain amino acids, caffeine and a source of carbohydrates including waxy maize. The dietary supplement may further comprise one or more of Ginseng providing ginsenoside saponins, and Fenugreek seeds providing 4-Hydroxyisoleucine.

Abstract: The present invention is directed to methods, kits and compositions for modulating the activity of Stat molecules (e.g., Stat1, Stat3 and Stat5). The compounds of the invention are useful for treating and/or preventing disorders characterized by Stat dysregulation, such as hyperproliferative disorders. Further, the compounds of the present invention are also useful in culturing stem cells and treating ischemic disorders.

Abstract: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.

Abstract: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.

Abstract: Polymer surfaces coated with organometallic layers, wherein the organometallic layers and polymer surfaces have functional groups that react to bond the organometallic layer to the polymer surface with organometallic functional groups remaining unreacted for the subsequent covalent attachment of organic overlayers. Coating methods and coated articles are also disclosed.

Abstract: The present invention concerns the use of tricyclic terpenes chosen from the group consisting of fusicoccin, ophyobolins or cotylenins for the therapy and diagnosis of coagulation-correlated pathologies such as Bernard-Soulier syndrome (BSS), von Willebrand disease (vWD), Glanzmann's thrombasthenia or thrombocytopenia.

Abstract: Methods for treatment of ocular disorders using steroids modulate the effects of local and systemic hypoxic events mediated by hypoxia inducible factor-1 (HIF-1). Steroids that are useful as HIF-1 modulators include bufalin, digitoxigenin, digoxin, lanatoside C, strophantin K, uzarigenin, ouabain and proscillaridin. In some embodiments the ocular disorder is characterized by ischmia.

Abstract: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.

Abstract: A substance having a testosterone 5?-reductase inhibiting action, a hair papilla cell growth promoting action, a fibroblast growth factor-7 production promoting action, a vascular endothelial growth factor production promoting action or a bone morphogenetic protein-2 production promoting action, and a hair care product having this substance blended therein. A hair growth tonic, a testosterone 5?-reductase inhibitor, a hair papilla cell growth promoter, a fibroblast growth factor-7 production promoter, a vascular endothelial growth factor production promoter and a bone morphogenetic protein-2 production promoter each having this substance, such as corosolic acid, as an active ingredient thereof.

Abstract: Provided herein are ginsenoside compositions comprising at least 10% (w/w) of a protopanaxadiol type of ginsenoside suitable for administration to a subject. Also provided are methods using the ginsenoside compositions for reducing acetaldehyde concentrations, preventing or ameliorating a symptom of elevated acetaldehyde concentration, or reducing the risk of diseases or disorders caused by the intake of ethyl alcohol.

Abstract: Provided herein are methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions comprising chemosensory receptor ligands. Also provided herein are chemosensory receptor ligand compositions and the preparation thereof for the methods of the present invention.

Abstract: The present invention relates to a composition for improvement of exercise performance, fatigue recovery or prevention of oxidation response comprising Panax species plant leaves extract or processed product of the leaves extract, or mixture of the both as an active ingredient. The present composition comprising Panax species plant leaves extract or processed product of the leaves extract, or mixture of the both increases the exercise performance, inhibit the accumulation of fatigue markers in blood and prevents oxidation response, and thus is useful to improve physical strength and exercise capacity.

Abstract: Compositions and methods for drug delivery are disclosed.

Abstract: The present invention relates to the use of a plant of the genus, Capsicum, or part thereof or extract thereof for treating or alleviating the symptoms of a skin condition or disorder, including dermatitis. The present invention also relates to compositions comprising the same for such use, together with methods of treating or alleviating the symptoms of eczema or dermatitis.

Abstract: A method of preparing medicaments for treating dilated cardiomyopathy includes the step of applying ginsenoside Rb1. Long-term treatment of ginsenoside Rb1 can reduce the mortality rate, improve the cardiac function, reduce the dilation of the left ventricular, reduce the hypertrophy of myocytes and the proliferation of collagen, reduce the uneven thickness of myocytes, mitochondrial swelling, break of crista, sarcoplasmic reticulum expansion and destruction of intercalated disc connection, increase the expression of connexin Cx40, E-cadherin and P-cadherin, fibroblast growth factor FGF2, FGF7, FGF8, FGF10, and reduce the expression of integrin Itga8 and Itgbp.

Abstract: The invention provides VEGFxxxb, or an agent which selectively promotes the expression of VEGFxxxb in preference to VEGFxxx in cells of a subject or in vitro, or an expression vector system which causes the expression of the VEGFxxxb in a host organism, for use in treating or preventing neuropathic and neurodegenerative disorders, or for use as a neuroprotective or neuroregenerative agent in vivo or in vitro. The VEGFxxxb is preferably VEGF165b.

Abstract: The present invention relates to use of an active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt for preparing a medicament and a health care product for improving sexual function of male mammals, and for providing the effect of spermatogenesis. The present invention further relates to a pharmaceutical composition for improving sexual function of male mammals, and/or for providing the effect of spermatogenesis, which comprises at least one active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt, and a pharmaceutically acceptable excipient.

Abstract: The present invention relates to a combination, such as a combined preparation or pharmaceutical composition comprising: (a) compound of formula (I), and/or (II) or a pharmaceutically acceptable salt thereof; (b) at least one therapeutic agent selected from the group consisting of: an antihypertensive agent; an antidiabetics agent; a hypolipidemic agent; an antiplatelet agent; an antiobesity agent; an antithrombotic agent; an agent for diabetic vascular complications; and an agent for treatment of heart failure; or a pharmaceutically acceptable salts thereof, optionally in presence of a pharmaceutically acceptable carrier for separate, simultaneous or sequential use. The present invention also relates to a use of such combination for the treatment of mammal including human being. R1, R2, R3, R1, R2, R3, R4, R5, X, Y, A and B and m are as defined in the specification.

Abstract: Disclosed are uses of an ocular irritant such as saponin in stimulating the retrobulbar blood flow of an eye. Disclosed are also methods of treatment including administration of a pharmaceutical composition including an ocular irritant to an eye, for example as a mist, in order to stimulate the retrobulbar blood flow. In some embodiments, the stimulation of the retrobulbar blood flow has a beneficial effect.

Abstract: The present invention relates to the use of an agent to combat and reduce the irritating action of primary surfactants in compositions to be applied to the skin for care or cleansing of the face and body, characterized in that said agent is chosen from Cone or more salts of glycyrrhizic acid, such as monoammonium glycyrrhizinate (MAG) and dipotassium glycyrrhizinate (DPG).

Abstract: Disclosed is an AMPK activating material used for improving and treating metabolic syndrome, in which AMPK (AMP-activated protein kinase) is a main enzyme for regulating an energy sensor and lipid/glucose metabolism in the body. The activation of AMPK inhibits the synthesis of fat and cholesterol, and accelerates the reduction of body fat and blood glucose, thereby improving obesity, diabetes, and hyperlipidaemia. The disclosed AMPK activating material contains, as active ingredients having an improving and treating effect on metabolic syndrome, including obesity, diabetes, and hyperlipidaemia, a novel compound 2?,3?,12?-trihydroxydammar-20(22)-E,24-diene-3-O-[?-D-glucopyranosyl-(1?)-?-D-glucopyranoside], named Damulin A, and a novel compound 2?,3?,12?-trihydroxydammara-20,24-diene-3-O-[?-D-glucopyranosyl-(1?)-?-D-glucopyranoside], named Damulin B.

Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1, R2, R3, R8, and R9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

Abstract: A method for treating symptoms or diseases associated with accumulation of abnormal protein in the body includes administrating to a subject desiring such treatment a composition containing silybin and soybean saponin in an amount effective to reduce or remove abnormal protein produced in the body.

Abstract: A compound of formula (I): wherein R1 is selected from the group consisting of H, ?-L-Rhamnopyranose, ?-D-Mannopyranose, ?-D-Xylopyranose, ?-D-Glucopyranose, and ?-D-Arabinopyranose; R2 is selected from CH3, COOH, CH2OH, COOCH3 and CH2O-?-D-Arabinopyranose; with the proviso that the compound of formula (I) is not a compound of formula (I) wherein R1 is ?-D-Glucopyranose and R2 is COOH; wherein R1 is ?-L-Rhamnopyranose and R2 is CH3; wherein R1 is ?-D-Glucopyranose and R2 is CH2OH; wherein R1 is ?-D-Xylopyranose and R2 is CH2OH; wherein R1 is ?-L-Rhamnopyranose and R2 is COOCH3, wherein R1 is H and R2 is CH3; wherein R1 is H and R2 is CH2OH; wherein R1 is H and R2 is COOH; or wherein R1 is H and R2 is COOCH3, or a pharmaceutically acceptable salt thereof.

Abstract: It is an object of the invention to discover a substance that effectively increases the production of adrenomedullin, as well as to provide an adrenomedullin production-enhancing agent utilizing this substance. The adrenomedullin production-enhancing agent is characterized by inclusion of a ginsenoside, a sanshool, and/or a shogaol as active ingredients.

Abstract: A method of treating volume expansion mediated hypertension including administering a therapeutically effective dose of resibufogenin to a patient having volume expansion mediated hypertension. A method for the determination of the presence of volume expansion mediated hypertension may be by determining whether there has been a substantial elevation in marinobufagenin which may be blood-derived or urine-derived and if such elevation does exist, concluding that volume expansion mediated hypertension does exist. The method may advantageously be practiced by employing urine, blood serum or blood plasma as the body specimen in determining whether a patient has volume expansion mediated hypertension. In another embodiment, bufodienolide derivatives other than resibufogenin may be employed in lieu of thereof or in combination therewith. In another embodiment, resibufogenin analogues may be employed in the treatment of volume expansion mediated hypertension.

Abstract: The present invention relates to compounds according to formula (I): wherein R2 is absent or a linking moiety and R3 is selected from the group consisting of anti- inflammatory agents and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising compounds of formula (I) and the use of these pharmaceutical compositions for the treatment or prophylaxis of chronic inflammatory diseases, in particular those that are caused by chronically activated macrophages. The chronic inflammatory disease is in particular atherosclerosis, (rheumatoid) arthritis, an (auto) immune disease or sarcoidosis.

Abstract: Oral pharmaceutical compositions or functional foods with a mechanism of multi-target receptor retroaction for treating depression comprising ginseng saponin (Rg1+Rb1), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating depression Paroxetine in the art, the present invention has significant anti-depression efficacy.

Abstract: Pharmaceutical compositions or functional foods for treating depression and anxiety comprising ginseng saponin (Rg1+Rb1), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating depression and anxiety paroxetine and diazepam in the art, the present invention has significant anti-depression and anxielytic efficacy.

Abstract: Pharmaceutical compositions or functional foods for treating anxiety comprising ginseng saponin (Rg1+Rb1), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating diazepam in the art, the present invention has significant anxielytic efficacy.

Abstract: To reduce amounts of fat accumulated in abdominal cavity and to prevent or ameliorate visceral fat type obesity considered to be a main factor of metabolic syndrome, there is provided an agent or a food or drink, including as an active ingredient 3-O-?-D-glucopyranosyl-4-methylergost-7-en-3-ol, an organic solvent extract, a hot water extract, a squeezed liquid of a Liliaceae plant or a fraction thereof which contains the compound.

Abstract: The present invention relates to methods for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The method and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin aliments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.

Abstract: The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridines, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

Abstract: The present invention provides a system for delivery of an enteric coated active agent generally resistant to disintegration in an neutral environment having one or more active agents encapsulated by a polymer coating formed by chemical vapor deposition of one or more monomers on the one or more active agents to form a chemical vapor deposition polymer coating that controls the release of the one or more active agents in the gastrointestinal tract.

Abstract: The invention relates to a crystalline form of 1?-(1-methylethyl)-4?-[(2-fluoro-4-methoxyphenyl)methyl]-5?-methyl-1H-pyrazol-3?-O-?-D-glucopyranoside, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.

Abstract: Provided is a sugar-cholestanol compound which can be readily synthesized, and which exhibits a satisfactory antitumor activity. An anticancer agent containing, as an active ingredient, a cholestanol compound represented by the following formula (1): or a cyclodextrin inclusion complexation containing the compound.

Abstract: The present invention provides a use of ginsenosides represented by formula I or mixtures thereof for manufacturing a medicament for anti-platelet aggregation, wherein R1 and R2 are H or glucosyl, and when R1 is glucosyl, R2 is H; when R1 is H, R2 is glucosyl. The present invention further provides a pharmaceutical composition for anti-platelet aggregation, which is capable to be used to prevent and treat thrombosis. The present invention also provides a method for generating the effect of anti-platelet aggregation in patients in vivo.

Abstract: The present invention relates to compounds, as well as to compositions, methods and kits comprising such compounds, for use in the treatment or prophylaxis of fibromyalgia, chronic fatigue syndrome, myofascial pain syndrome, Gulf War syndrome and related conditions, wherein the compound is a fatty acid oxidation inhibitor and/or a carbohydrate oxidation activator.

Abstract: A method for the treatment and/or prophylaxis of a viral infection in a subject is provided wherein the method comprises the steps of providing a therapeutically effective amount of a composition comprising an extract of the fruit of Siraitia grosvenori Swingle and administering the composition to the subject. The fruit from which the extract is derived is Luo Han Guo. The extract comprises at least one thterpene glycoside, which may be in the form of a mogroside compound. The extract has been shown to be effective in the treatment of viral infections such as hepatitis C and HIV. Also provided are pharmaceutical compositions comprising at least one thterpene glycoside, or an analogue, metabolite, precursor, derivative, pharmaceutically active salt or pro-drug thereof.

Abstract: Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.

Abstract: Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein.

Abstract: This invention relates to novel quinazoline derivatives, and their pharmaceutically acceptable salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibiting cell surface tyrosine receptor kinases.

Abstract: The invention relates to a composition containing total triterpenoid sapogenins extracted from bamboo, the preparation method and use thereof. These total triterpenoid sapogenins are extracted from many parts of bamboo such as bamboo shavings in Gramineae by CO2 Supercritical Fluid Extraction technique. In the extract, the content of total triterpenoid sapogenins is 10-90%, while the contents of friedelin and lupenone are 5-35% and 1-10%, respectively. The extract in the invention has good physiological and pharmacological activities such as anti-free radical, anti-oxidation, anti-tumor and anti-hypertension. It can be used in medicines or functional foods for the treatment or prevention of cardiovascular and cerebrovascular diseases and tumor. It is also useful in cosmetics field.